Risankizumab-rzaa
Risankizumab-rzaa
Risankizumab-rzaa (pronounced as ris an kiz' ue mab) is a monoclonal antibody used in the treatment of moderate to severe plaque psoriasis. It is marketed under the brand name Skyrizi.
Etymology
The name Risankizumab-rzaa is derived from the International Nonproprietary Names (INN) system for pharmaceutical substances. The "-mab" suffix indicates it is a monoclonal antibody, "-zu-" denotes humanized antibody, "-ki-" signifies the target which is the interleukin (IL) and "-ris" is a random prefix.
Usage
Risankizumab-rzaa is used for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It works by binding to the p19 subunit of interleukin 23 (IL-23) and inhibiting its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Plaque Psoriasis: A condition characterized by raised, red areas on the skin covered with a white buildup of dead skin cells.
- Interleukin 23: A cytokine that plays an important role in managing the immune system and inflammation.
Side Effects
Common side effects of Risankizumab-rzaa include upper respiratory infections, headache, fatigue, injection site reactions, and fungal infections.
See Also
External links
- Medical encyclopedia article on Risankizumab-rzaa
- Wikipedia's article - Risankizumab-rzaa
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski